Medical School · Year 2 · Pathology · includes a quiz and discussion video

Lecture 06: Neoplasia - Basic Concepts

Unit 2.11: Pathology

Learning Objectives

By the end of this lecture, students will be able to:

1. Define neoplasia and describe tumor nomenclature
2. Explain the differences between benign and malignant tumors
3. Describe oncogenes and their mechanisms of activation
4. Explain tumor suppressor genes and their role in cancer
5. Describe the hallmarks of cancer
6. Explain the molecular basis of carcinogenesis

Lecture Outline

I. Introduction to Neoplasia

Neoplasia literally means "new growth" and refers to the abnormal proliferation of cells that persists even after cessation of the stimuli that initiated the change, distinguishing it from hyperplasia which regresses when the stimulus is removed. A neoplasm is an abnormal mass of tissue whose growth exceeds and is uncoordinated with that of the normal tissues and persists in the same excessive manner after cessation of the stimulus that evoked the change. The common term "tumor" was originally used to describe any swelling but is now essentially synonymous with neoplasm. Cancer specifically refers to malignant neoplasms that have the capacity to invade surrounding tissues and metastasize to distant sites.

All tumors, whether benign or malignant, have two basic components that determine their behavior and appearance. The parenchyma consists of the neoplastic cells themselves, which determine the tumor's biologic behavior and provide the basis for classification and nomenclature. The stroma consists of connective tissue, blood vessels, and inflammatory cells that provide structural support and nutrition to the parenchyma but are not themselves neoplastic. Desmoplasia refers to the dense fibrous stromal response that some tumors induce, creating a hard, scirrhous consistency particularly characteristic of certain breast and gastric carcinomas.

The distinction between benign and malignant tumors has profound clinical and prognostic implications for patient management and outcomes. Benign tumors remain localized at their site of origin, do not invade surrounding tissues, and do not metastasize to distant sites. While benign tumors may cause significant morbidity through compression of adjacent structures, hormone production, or obstruction, they are generally curable by surgical excision and rarely cause death. Malignant tumors invade and destroy adjacent structures and can spread to distant sites through metastasis, making complete surgical excision difficult or impossible and potentially causing death.

The clinical importance of neoplasia cannot be overstated, as cancer is the second leading cause of death in developed countries, exceeded only by cardiovascular disease. The lifetime risk of developing cancer in the United States is approximately one in three for women and one in two for men. Cancer incidence varies significantly by site, with prostate cancer most common in men and breast cancer most common in women, though lung cancer remains the leading cause of cancer death in both sexes. Understanding the fundamental biology of neoplasia is essential for prevention, early detection, and treatment of cancer.

<image>Panel A: Diagram illustrating the two components of neoplasms - parenchyma (neoplastic cells) and stroma (supportive connective tissue, blood vessels) - shown in cross-section of a tumor mass with desmoplastic stromal response. Panel B: Comparison of benign versus malignant tumor characteristics showing localized growth with capsule versus invasive growth with irregular borders. Panel C: Graph showing cancer as leading cause of death with incidence rates for common cancers in men (prostate, lung, colorectal) and women (breast, lung, colorectal). Panel D: Timeline showing progression from normal cell through initiation, promotion, and progression to invasive cancer and metastasis.</image>

II. Tumor Nomenclature

The nomenclature of tumors follows systematic conventions that indicate both the cell of origin and whether the tumor is benign or malignant. For benign tumors arising from mesenchymal tissues, the suffix "-oma" is added to the cell type of origin: lipoma from fat cells, fibroma from fibrous tissue, chondroma from cartilage, osteoma from bone, leiomyoma from smooth muscle, and hemangioma from blood vessels. Benign epithelial tumors have more varied nomenclature: adenoma refers to benign tumors forming glandular patterns or arising from glands, papilloma describes benign tumors producing finger-like projections from epithelial surfaces, and cystadenoma designates cystic adenomas.

Malignant tumors arising from mesenchymal tissues are designated sarcomas, with the cell type of origin indicated in the prefix. Liposarcoma arises from fat, fibrosarcoma from fibrous tissue, chondrosarcoma from cartilage, osteosarcoma from bone, leiomyosarcoma from smooth muscle, and angiosarcoma from blood vessel endothelium. Sarcomas are relatively uncommon, accounting for less than 1% of all malignant tumors, but are often highly aggressive with propensity for hematogenous metastasis. Their mesenchymal origin distinguishes them from the more common epithelial malignancies.

Malignant tumors arising from epithelial cells are called carcinomas and account for the vast majority of human cancers. Adenocarcinoma refers to carcinoma with glandular growth pattern or arising from glandular epithelium. Squamous cell carcinoma arises from stratified squamous epithelium or shows squamous differentiation with features such as keratin production or intercellular bridges. Transitional cell carcinoma (now more commonly called urothelial carcinoma) arises from the urothelium lining the urinary tract. The term "undifferentiated carcinoma" is applied when the tumor is clearly epithelial but lacks distinguishing features.

Several tumors have names that do not follow standard nomenclature conventions and must be memorized as exceptions to the rules. Melanoma is a malignant tumor of melanocytes, despite the "-oma" suffix typically indicating benign tumors. Lymphoma refers to malignant proliferations of lymphocytes, and leukemia denotes malignant proliferation of white blood cell precursors in bone marrow. Seminoma is a malignant germ cell tumor of the testis, and mesothelioma is a malignant tumor of mesothelial cells lining body cavities. These exceptions highlight the importance of learning specific tumor terminology rather than relying solely on general rules.

<image>Panel A: Systematic chart of benign tumor nomenclature showing cell of origin (fat, fibrous, cartilage, bone, smooth muscle, blood vessel, gland, epithelial surface) and corresponding benign tumor names (lipoma, fibroma, chondroma, osteoma, leiomyoma, hemangioma, adenoma, papilloma). Panel B: Corresponding chart for malignant tumors showing sarcoma nomenclature (liposarcoma, fibrosarcoma, chondrosarcoma, osteosarcoma, leiomyosarcoma) and carcinoma types. Panel C: Histologic comparison of adenoma versus adenocarcinoma and papilloma versus squamous cell carcinoma showing architectural and cytologic differences. Panel D: List of tumors with non-standard nomenclature (melanoma, lymphoma, leukemia, seminoma, mesothelioma) with notation that these are malignant despite names.</image>

III. Benign vs Malignant Tumors

Benign tumors are characterized by their localized growth pattern, remaining confined to their site of origin without invasion of surrounding tissues or metastasis. The gross appearance typically shows well-demarcated margins, often with a fibrous capsule that separates the tumor from surrounding normal tissue. This encapsulation facilitates surgical excision, as the tumor can be "shelled out" from its bed with minimal risk of leaving residual disease. The growth of benign tumors is typically slow and may plateau, with some tumors remaining stable for years or even regressing, and mitotic figures are few in number and typically normal in appearance.

The cytologic features of benign tumors closely resemble those of the normal cell of origin, a property termed differentiation. Well-differentiated tumor cells maintain the structural and functional characteristics of their normal counterparts, making identification of the cell of origin straightforward. A lipoma consists of mature adipocytes nearly indistinguishable from normal fat cells. An adenoma maintains glandular architecture with uniform cells showing low nuclear-to-cytoplasmic ratios, regular nuclear contours, and evenly distributed chromatin. Necrosis is rare in benign tumors because their slow growth allows adequate blood supply to develop.

Malignant tumors are distinguished from benign tumors by three fundamental properties: invasion, metastasis, and typically more rapid growth with less differentiation. Invasion refers to the ability of malignant cells to penetrate basement membranes and infiltrate surrounding tissues, destroying normal structures in their path. Unlike benign tumors, which grow as expansile masses that push aside normal tissue, malignant tumors have irregular, poorly demarcated borders that extend into adjacent structures, often lacking a capsule. The presence of necrosis is common in malignant tumors due to rapid growth outpacing blood supply.

The cytologic features of malignant tumors include varying degrees of anaplasia, the loss of cellular differentiation that characterizes cancer cells. Anaplastic features include pleomorphism (variation in cell and nuclear size and shape), abnormal nuclear morphology with hyperchromasia (dark-staining nuclei) and irregular nuclear contours, increased nuclear-to-cytoplasmic ratio, prominent nucleoli, loss of normal tissue polarity, and abundant mitoses including atypical forms such as tripolar or multipolar mitotic figures. Tumor giant cells may be present as another manifestation of anaplasia. Tumor grading from Grade 1 (well differentiated) to Grade 4 (undifferentiated/anaplastic) correlates with prognosis.

<image>Panel A: Gross photograph of encapsulated benign tumor showing well-demarcated borders with fibrous capsule, compared to invasive malignant tumor with irregular margins infiltrating surrounding tissue. Panel B: Histologic features showing benign adenoma with uniform glandular architecture and low mitotic rate versus adenocarcinoma with irregular glands, cytologic atypia, and increased mitoses. Panel C: Features of anaplasia including pleomorphism, nuclear hyperchromasia, increased N:C ratio, prominent nucleoli, loss of polarity, and tumor giant cells with corresponding histologic images. Panel D: Tumor grading comparison showing Grade 1 (well differentiated), Grade 2 (moderately differentiated), Grade 3 (poorly differentiated), and Grade 4 (undifferentiated/anaplastic).</image>

IV. Local Invasion and Metastasis

Local invasion distinguishes malignant from benign tumors and reflects the ability of cancer cells to breach tissue barriers and infiltrate surrounding structures. Benign tumors grow as expansile masses that compress but do not invade adjacent tissues, typically developing a fibrous capsule at the interface between tumor and normal tissue. Malignant tumors lack a capsule and extend irregularly into surrounding tissue, making surgical margins critical and contributing to local recurrence when tumor cells remain after resection. The invasive front of a carcinoma often shows loss of E-cadherin and epithelial-to-mesenchymal transition, enabling detachment and migration.

Metastasis, the spread of tumor from its primary site to distant organs, is the defining characteristic of malignancy and the major cause of cancer-related death. The metastatic cascade is a complex multi-step process requiring cancer cells to detach from the primary tumor, invade local tissues, enter blood or lymphatic vessels (intravasation), survive in the circulation, exit vessels at distant sites (extravasation), and establish growth in the foreign microenvironment. Only a small fraction of circulating tumor cells successfully complete this cascade, but those that do establish secondary tumors that are often resistant to therapy.

The routes of metastasis include lymphatic spread, hematogenous spread, and seeding of body cavities. Carcinomas tend to spread initially through lymphatics to regional lymph nodes, making nodal involvement an important staging and prognostic factor. Sarcomas preferentially spread hematogenously, often to the lungs which serve as the first capillary bed encountered by venous tumor emboli. The pattern of hematogenous metastasis reflects the vascular drainage of the primary site: colon cancer frequently metastasizes to the liver via portal venous drainage. Direct seeding of body cavities, particularly the peritoneum and pleura, occurs with tumors that reach the serosal surface.

Certain cancers show characteristic patterns of metastatic spread that may reflect either anatomic drainage or specific tropism for certain organ microenvironments. Breast cancer commonly metastasizes to bone, lung, liver, and brain. Prostate cancer typically produces osteoblastic (bone-forming) metastases in the axial skeleton. Lung cancer spreads to brain, bone, and adrenal glands. Melanoma is notorious for metastasizing to virtually any site including unusual locations like the small intestine. Understanding these patterns guides clinical surveillance and informs treatment planning for patients with cancer.

<image>Panel A: Comparison of benign tumor growth (expansile, encapsulated) versus malignant tumor invasion (irregular borders, infiltrating adjacent tissue, destroying basement membrane). Panel B: The metastatic cascade illustrated step-by-step: detachment, local invasion, intravasation, circulation, extravasation, and establishment of metastatic colony. Panel C: Routes of metastasis showing lymphatic spread to regional nodes (typical of carcinomas), hematogenous spread to lungs, liver, and other organs (typical of sarcomas), and body cavity seeding. Panel D: Common metastatic patterns showing breast cancer spreading to bone, lung, liver, and brain; colon cancer to liver; prostate cancer to bone with osteoblastic lesions; melanoma spreading to any site.</image>

V. Hallmarks of Cancer

The hallmarks of cancer, proposed by Hanahan and Weinberg, provide a conceptual framework for understanding the complex biology of neoplasia as a set of acquired capabilities that distinguish cancer cells from normal cells. Sustaining proliferative signaling represents the ability of cancer cells to proliferate without external stimulation, achieved through autocrine growth factor production, receptor amplification or mutation, and constitutive activation of downstream signaling pathways. Evading growth suppressors involves inactivation of tumor suppressor pathways including RB and TGF-beta signaling that normally restrain proliferation. Together, these capabilities uncouple cell division from normal regulatory controls.

Resisting cell death is essential for cancer cell survival in the face of cellular stresses and genomic damage that would normally trigger apoptosis. Mechanisms include loss of p53 function, overexpression of anti-apoptotic BCL2 family members, and loss of pro-apoptotic factors. Enabling replicative immortality overcomes the normal limit on cell division imposed by telomere shortening. Most somatic cells lack telomerase activity and undergo replicative senescence after a fixed number of divisions, but cancer cells typically reactivate telomerase or use alternative lengthening of telomeres (ALT) to maintain telomere length and achieve immortality.

Inducing angiogenesis provides the blood supply necessary for tumor growth beyond the diffusion limit of oxygen (approximately 1-2 mm). Tumors induce angiogenesis by shifting the balance between pro-angiogenic factors (VEGF, FGF) and anti-angiogenic factors (thrombospondin, angiostatin). The angiogenic switch, often occurring during progression from in situ to invasive carcinoma, is driven by hypoxia, oncogene activation, and loss of p53. Activating invasion and metastasis represents the culmination of malignant progression, requiring loss of cell-cell adhesion through epithelial-mesenchymal transition, acquisition of motility, and proteolytic destruction of extracellular matrix.

Emerging hallmarks and enabling characteristics expand the original framework. Deregulating cellular energetics involves the shift to aerobic glycolysis known as the Warburg effect, where cancer cells preferentially use glycolysis even in the presence of oxygen, supporting biosynthetic demands of rapidly dividing cells and detectable by PET scan using FDG uptake. Avoiding immune destruction reflects the ability of tumors to escape immune surveillance. Genomic instability enables the acquisition of other hallmarks by increasing mutation rates. Tumor-promoting inflammation provides growth factors, survival signals, and angiogenic factors that support tumor development.

<image>Panel A: Diagram illustrating the six original hallmarks of cancer - sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis - arranged around a central tumor cell. Panel B: The angiogenic switch showing balance between pro-angiogenic (VEGF) and anti-angiogenic factors, with hypoxia and oncogene activation tipping the balance toward angiogenesis. Panel C: Warburg effect diagram comparing normal cell oxidative phosphorylation with cancer cell aerobic glycolysis even with oxygen available, providing biosynthetic intermediates and the basis for PET imaging with FDG. Panel D: Updated hallmarks diagram including emerging hallmarks (metabolic reprogramming, immune evasion) and enabling characteristics (genomic instability, tumor-promoting inflammation).</image>

VI. Oncogenes

Proto-oncogenes are normal cellular genes that promote cell proliferation and differentiation during development and tissue homeostasis. When mutated or overexpressed, proto-oncogenes become oncogenes that drive uncontrolled cell proliferation. The mutations that activate oncogenes represent gain-of-function alterations that are dominant at the cellular level, meaning mutation of a single allele is sufficient to promote cancer development. Oncogenes can be classified by the function of their encoded proteins into growth factors, growth factor receptors, signal transduction molecules, nuclear transcription factors, and cell cycle regulators.

Mechanisms of oncogene activation include point mutations that produce constitutively active proteins, gene amplification resulting in protein overexpression, and chromosomal translocations that create fusion genes or place genes under control of strong promoters. The RAS family of small GTPases represents the most commonly mutated oncogenes in human cancer, with mutations found in approximately 30% of all cancers, including 90% of pancreatic cancers and 50% of colon cancers. Normal RAS cycles between an active GTP-bound state and an inactive GDP-bound state, but oncogenic mutations at codons 12, 13, or 61 impair GTPase activity, locking the protein in the constitutively active state.

Growth factor receptors are frequently activated in cancer through amplification or mutation, producing ligand-independent signaling that drives proliferation. The epidermal growth factor receptor (EGFR) is amplified in glioblastoma and mutated in lung adenocarcinoma, providing targets for tyrosine kinase inhibitors. HER2/neu (ERBB2) is amplified in approximately 20% of breast cancers, providing a target for trastuzumab therapy. The RET receptor tyrosine kinase is activated by point mutation in familial medullary thyroid carcinoma. These receptor alterations produce continuous growth signals independent of ligand binding.

Chromosomal translocations play a prominent role in hematologic malignancies by creating fusion genes with oncogenic properties or placing genes under control of strong promoters. The Philadelphia chromosome, t(9;22), creates the BCR-ABL fusion in chronic myeloid leukemia, producing a constitutively active tyrosine kinase that is effectively targeted by imatinib. The t(8;14) translocation in Burkitt lymphoma places MYC under control of the immunoglobulin heavy chain promoter, causing MYC overexpression. Gene amplification activates HER2 in breast cancer and N-MYC in neuroblastoma, where N-MYC amplification correlates with poor prognosis.

<image>Panel A: Classes of oncogene products arranged in a signaling pathway from growth factors (PDGF) through receptors (EGFR, HER2, RET), signal transduction (RAS, ABL, BRAF), nuclear transcription factors (MYC, JUN, FOS), to cell cycle regulators (Cyclin D, CDK4). Panel B: RAS GTPase cycle showing normal cycling between active (GTP-bound) and inactive (GDP-bound) states, with oncogenic mutations at codons 12, 13, 61 blocking GTPase activity and locking RAS in active state with continuous growth signals. Panel C: Mechanisms of oncogene activation including point mutation (RAS), chromosomal translocation (BCR-ABL, MYC), and gene amplification (HER2, N-MYC) with clinical examples. Panel D: Philadelphia chromosome formation showing t(9;22) translocation creating BCR-ABL fusion gene with constitutive tyrosine kinase activity and therapeutic targeting by imatinib.</image>

VII. Tumor Suppressor Genes

Tumor suppressor genes normally function to restrain cell proliferation, and their inactivation removes the brakes on cell division allowing uncontrolled growth. Unlike oncogene activation, tumor suppressor gene inactivation typically requires loss of both alleles according to the two-hit hypothesis first proposed by Knudson based on analysis of retinoblastoma. The first hit may be inherited (as in hereditary cancer syndromes) or acquired; the second hit inactivates the remaining normal allele. Mechanisms of inactivation include mutation, deletion, and epigenetic silencing through promoter methylation.

The RB gene, the first tumor suppressor gene discovered, encodes a nuclear phosphoprotein that controls the G1 to S phase transition of the cell cycle. In its hypophosphorylated state, RB binds and inhibits E2F transcription factors that activate genes required for DNA synthesis. Growth factor signaling leads to RB phosphorylation by cyclin-dependent kinases (CDK4/6), releasing E2F and permitting cell cycle progression. Loss of RB function through mutation, deletion, or binding by viral oncoproteins (HPV E7, adenovirus E1A) removes this checkpoint. Germline RB mutations cause hereditary retinoblastoma with increased risk of osteosarcoma.

The TP53 gene, termed the "guardian of the genome," encodes a transcription factor that responds to cellular stress by inducing cell cycle arrest, DNA repair, senescence, or apoptosis. p53 is the most commonly mutated gene in human cancer, with alterations in approximately 50% of all tumors. When DNA damage occurs, p53 is stabilized and activates transcription of target genes including p21 (a CDK inhibitor causing cell cycle arrest), GADD45 (DNA repair), and BAX (promoting apoptosis). Loss of p53 function allows cells with DNA damage to continue proliferating, accumulating additional mutations. Germline TP53 mutations cause Li-Fraumeni syndrome with dramatically elevated lifetime cancer risk.

Additional important tumor suppressors include APC, which functions in the Wnt signaling pathway by promoting degradation of beta-catenin, with germline mutations causing familial adenomatous polyposis and sporadic mutations occurring early in colorectal carcinogenesis. BRCA1 and BRCA2 function in DNA double-strand break repair through homologous recombination, with germline mutations causing hereditary breast and ovarian cancer syndrome with lifetime breast cancer risk of 50-85%. VHL regulates hypoxia-inducible factor (HIF) and is mutated in hereditary renal cell carcinoma. NF1 encodes neurofibromin, a RAS inhibitor, with loss causing neurofibromatosis type 1.

<image>Panel A: Two-hit hypothesis for tumor suppressor inactivation showing sporadic cancer (two somatic hits) versus hereditary cancer (one germline hit plus one somatic hit), with Knudson's retinoblastoma model illustrating earlier onset with hereditary form. Panel B: RB protein function showing hypophosphorylated RB binding and inhibiting E2F, growth factor signaling causing cyclin D-CDK4/6 phosphorylation of RB, release of E2F and S phase entry. Panel C: p53 pathway showing activation by DNA damage, transcriptional targets (p21 for cell cycle arrest, GADD45 for DNA repair, BAX for apoptosis), and consequences of p53 loss including Li-Fraumeni syndrome. Panel D: Major tumor suppressor genes showing RB1 (retinoblastoma), TP53 (Li-Fraumeni), APC (FAP/colorectal), BRCA1/2 (breast/ovarian), VHL (renal), NF1 (neurofibromatosis) with their functions and associated cancers.</image>

VIII. DNA Repair Genes and Carcinogenic Agents

Caretaker genes maintain genome integrity, and their loss accelerates the accumulation of mutations that drive carcinogenesis. Mismatch repair genes (MLH1, MSH2, and others) correct errors made during DNA replication, with germline mutations causing Lynch syndrome (hereditary nonpolyposis colorectal cancer) characterized by increased risk of colorectal, endometrial, and other cancers. Tumors with mismatch repair deficiency exhibit microsatellite instability, defined as variation in the length of repetitive DNA sequences detectable by PCR or immunohistochemistry for MMR proteins. Microsatellite instability-high tumors show improved response to immune checkpoint inhibitors, making this an important biomarker.

BRCA1 and BRCA2 function in homologous recombination repair of DNA double-strand breaks, and when mutated, cells cannot accurately repair these lesions and rely on error-prone repair pathways. This creates a therapeutic vulnerability exploited by PARP inhibitors, which block an alternative repair pathway (base excision repair) and cause synthetic lethality specifically in BRCA-deficient cells while sparing normal cells with intact homologous recombination. Tumors with BRCA mutations also show increased sensitivity to platinum-based chemotherapy due to the DNA crosslinks these drugs produce.

Chemical carcinogens contribute to cancer through DNA damage and mutation through two main categories. Direct-acting carcinogens such as alkylating agents used in chemotherapy can directly modify DNA without metabolic processing. Indirect-acting carcinogens (procarcinogens) require metabolic activation to become carcinogenic; examples include polycyclic aromatic hydrocarbons in tobacco smoke and aflatoxin B1 produced by Aspergillus fungi that causes hepatocellular carcinoma. Chemical carcinogenesis involves initiation (irreversible DNA damage) and promotion (stimulation of proliferation of initiated cells).

Radiation and infectious agents are important carcinogens that merit attention. Ultraviolet radiation causes pyrimidine dimers in DNA, leading to skin cancers; the DNA repair defect in xeroderma pigmentosum illustrates the critical importance of UV damage repair. Ionizing radiation causes DNA strand breaks and increases risk of leukemia and solid tumors. Oncogenic viruses include HPV (cervical and oropharyngeal carcinoma via E6 and E7 oncoproteins), EBV (Burkitt lymphoma, nasopharyngeal carcinoma, Hodgkin lymphoma), HBV and HCV (hepatocellular carcinoma through chronic inflammation), HTLV-1 (adult T-cell leukemia/lymphoma), and HHV-8 (Kaposi sarcoma). Helicobacter pylori, a bacterium, causes gastric adenocarcinoma and MALT lymphoma through chronic inflammation and the CagA oncoprotein.

<image>Panel A: Mismatch repair function showing MLH1/MSH2 proteins recognizing and repairing DNA replication errors, consequences of MMR deficiency (microsatellite instability), and Lynch syndrome cancer spectrum with associated organs. Panel B: BRCA1/2 function in homologous recombination repair of DNA double-strand breaks, and synthetic lethality with PARP inhibition causing selective death of BRCA-deficient tumor cells. Panel C: Chemical carcinogenesis showing direct-acting versus indirect-acting (procarcinogen requiring metabolic activation) pathways, initiation and promotion model, and examples (aflatoxin, polycyclic hydrocarbons, alkylating agents). Panel D: Oncogenic viruses showing HPV (cervical), EBV (Burkitt), HBV/HCV (hepatocellular), HTLV-1 (ATL), HHV-8 (Kaposi) with their mechanisms of oncogenesis (viral oncogenes, chronic inflammation).</image>

IX. Multi-Step Carcinogenesis

The development of cancer requires multiple genetic alterations, with the stepwise accumulation of mutations over years to decades transforming a normal cell into a fully malignant cancer capable of invasion and metastasis. This multi-step process is exemplified by the adenoma-carcinoma sequence of colorectal cancer, where specific genetic alterations correlate with histologic progression from normal epithelium through hyperplasia, early adenoma, intermediate adenoma, late adenoma, carcinoma in situ, and invasive carcinoma. APC loss occurs early, followed by RAS activation, SMAD4 loss, and finally TP53 loss in the progression to carcinoma, with additional mutations driving metastatic capability.

Clonal evolution underlies tumor progression, with tumors arising from a single transformed cell and evolving through successive rounds of mutation and selection. Mutations that confer a growth advantage are positively selected, leading to expansion of the mutant clone at the expense of less fit cells. Within a tumor, multiple subclones with different genetic alterations coexist, creating intratumoral heterogeneity that has profound implications for therapy. This genetic diversity provides raw material for selection of resistant clones during treatment, explaining why cancers often respond initially to therapy but subsequently relapse with resistant disease.

The distinction between driver and passenger mutations is critical for understanding cancer biology and developing targeted therapies. Driver mutations are those that contribute directly to cancer development by conferring a growth advantage, while passenger mutations do not contribute to cancer progression but accumulate as a consequence of genomic instability. The typical solid tumor contains a handful of driver mutations (often 3-8) and hundreds to thousands of passenger mutations. Identifying driver mutations is critical because they represent rational therapeutic targets, while recurrent mutations across tumors of the same type are likely to be drivers as they have been independently selected in multiple patients.

The cancer genome is characterized by genomic instability that accelerates the accumulation of mutations beyond what would occur in normal cells. Chromosomal instability causes gains and losses of whole chromosomes or chromosome arms, producing aneuploidy common in solid tumors. Microsatellite instability results from defective mismatch repair and is common in certain tumor types including Lynch syndrome-associated cancers. Point mutations accumulate at elevated rates when DNA repair or replication fidelity is impaired. This genomic instability, while contributing to tumor progression, also creates vulnerabilities that can be therapeutically exploited through targeting of specific repair defects.

<image>Panel A: Colorectal adenoma-carcinoma sequence showing histologic progression from normal epithelium through hyperplasia, early adenoma, intermediate adenoma, late adenoma, carcinoma, with corresponding genetic changes (APC loss, RAS activation, SMAD4 loss, TP53 loss) mapped to each stage. Panel B: Clonal evolution diagram showing origin from single transformed cell, successive rounds of mutation and selection creating a branching tree of subclones, and development of intratumoral heterogeneity. Panel C: Driver versus passenger mutations illustrated with typical numbers in solid tumors (few drivers providing growth advantage, many passengers as bystanders) and criteria for identifying drivers (recurrence across patients, functional impact). Panel D: Types of genomic instability showing chromosomal instability with aneuploidy, microsatellite instability from MMR defects, and elevated point mutation rates, with consequences for tumor heterogeneity and therapy resistance.</image>

X. Cancer Stem Cells and Tumor Microenvironment

The cancer stem cell hypothesis proposes that tumors are hierarchically organized, with a subset of cells possessing stem cell-like properties of self-renewal and differentiation that drive tumor growth and regeneration. According to this model, only cancer stem cells have the capacity for unlimited proliferation and tumor initiation, while the bulk of tumor cells are more differentiated progeny with limited proliferative potential. Cancer stem cells were first identified in acute myeloid leukemia and have subsequently been described in solid tumors including breast, brain, and colon cancer. This hierarchy has important therapeutic implications, as treatments that eliminate bulk tumor cells but spare cancer stem cells would result in relapse.

Cancer stem cells typically exhibit resistance to conventional chemotherapy and radiation therapy through multiple mechanisms including quiescence (non-dividing state that renders them resistant to agents targeting dividing cells), enhanced DNA repair, and expression of drug efflux pumps. Identification relies on functional assays demonstrating tumor-initiating capacity in serial transplantation experiments in immunodeficient mice. Cancer stem cells can be enriched using cell surface markers that vary by tumor type, such as CD44+/CD24- phenotype in breast cancer and CD133 in brain tumors. The cancer stem cell model remains an area of active investigation.

The tumor microenvironment comprises the non-neoplastic cells and extracellular matrix surrounding tumor cells, including cancer-associated fibroblasts, endothelial cells forming tumor vasculature, various immune cells, and extracellular matrix components. The microenvironment is not merely a passive bystander but actively contributes to tumor progression through growth factor secretion, angiogenesis, immune modulation, and matrix remodeling. Cancer-associated fibroblasts secrete growth factors, chemokines, and extracellular matrix components that support tumor growth and invasion, representing activated fibroblasts that differ from normal tissue fibroblasts.

Angiogenesis is essential for tumor growth beyond approximately 1-2 mm, as diffusion cannot supply oxygen and nutrients to larger masses. The angiogenic switch occurs when pro-angiogenic factors, particularly VEGF, outweigh anti-angiogenic factors. VEGF inhibitors such as bevacizumab have demonstrated clinical activity in several cancer types, though resistance develops through alternative angiogenic pathways. The immune microenvironment includes both tumor-promoting and tumor-inhibiting cell populations, and immune checkpoint inhibitors that release the brakes on anti-tumor T cell responses have revolutionized treatment of many cancers, particularly those with high mutation burden or microsatellite instability that generate immunogenic neoantigens.

<image>Panel A: Cancer stem cell model showing hierarchical organization with self-renewing cancer stem cells at apex generating transit-amplifying cells and differentiated tumor cells with limited proliferative capacity, with implications for therapy (need to target stem cells for cure). Panel B: Cancer stem cell properties including self-renewal demonstrated by serial transplantation, surface markers (CD44, CD133), and mechanisms of therapy resistance (quiescence, drug efflux pumps, enhanced DNA repair). Panel C: Tumor microenvironment components showing cancer-associated fibroblasts secreting growth factors, tumor vasculature, tumor-associated macrophages with both pro- and anti-tumor functions, and extracellular matrix with bidirectional signaling between tumor cells and stroma. Panel D: Angiogenesis in tumors showing the angiogenic switch with VEGF pathway, anti-angiogenic therapy targets, and the immune microenvironment with checkpoint inhibitor mechanisms releasing T cell anti-tumor activity.</image>

Summary

• Nomenclature: adenoma/carcinoma (epithelial), -oma/-sarcoma (mesenchymal); exceptions include melanoma, lymphoma, leukemia
• Benign tumors: well-differentiated, encapsulated, slow-growing, no invasion or metastasis
• Malignant tumors: anaplastic features (pleomorphism, hyperchromasia, high N:C ratio, mitoses), invasive, metastatic potential
• Routes of metastasis: lymphatic (carcinomas), hematogenous (sarcomas), body cavity seeding
• Hallmarks: proliferation, evade suppressors, resist death, immortality, angiogenesis, invasion; plus metabolic reprogramming and immune evasion
• Oncogenes: gain of function from point mutation (RAS), amplification (HER2), or translocation (BCR-ABL, MYC)
• Tumor suppressors: loss of function requiring two-hit inactivation; includes p53, RB, APC, BRCA1/2
• TP53: "guardian of genome" mutated in 50% of cancers; induces arrest or apoptosis in response to DNA damage
• Carcinogens: chemicals, radiation, viruses (HPV, EBV, HBV/HCV), and bacteria (H. pylori)
• Multi-step carcinogenesis: colorectal adenoma-carcinoma sequence as model; clonal evolution creates heterogeneity

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown